Zobrazeno 1 - 10
of 98
pro vyhledávání: '"W. E. Schmidt"'
Autor:
R Schlottmann, Thilo Gambichler, Markus Stücker, C Torres-Reyes, Ashwin Sriram, W E Schmidt, Judith Reuther, Jürgen C. Becker, René Stranzenbach, R Hayajneh
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Data on SARS‐CoV‐2 detection in lesional skin is controversial.1‐8 We report a PCR‐proven COVID‐19 patient with a chilblain‐like SARS‐CoV‐2 positive skin lesion. An 80‐year‐old woman presented to the emergency department at the En
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5922bf16d2e36c82d3c8974cb44761b8
https://www.ncbi.nlm.nih.gov/pubmed/33002210
https://www.ncbi.nlm.nih.gov/pubmed/33002210
Publikováno v:
Der Internist. 59(3)
Two female patients were admitted due to ketoacidosis. Serum glucose was moderately elevated. The patients exhibited abdominal and neurologic symptoms. Treatment consisted of metformin, insulin glargin and empagliflozin, as well as glimepiride, insul
Autor:
T G K, Breuer, H L, Breuer, B A, Menge, A, Giese, W, Uhl, W E, Schmidt, A, Tannapfel, D, Wild, M A, Nauck, J J, Meier
Publikováno v:
Der Internist. 57(4)
A 64-year-old woman presented with a history of recurrent hypoglycemia. A prolonged fasting test revealed an increased "amended" insulin-glucose ratio. Transabdominal ultrasound (US), computed tomography (CT) scan, and magnetic resonance imaging (MRI
Autor:
W. E. Schmidt
Publikováno v:
International Journal of Clinical Practice. 64:12-20
Summary Aims: To describe Phase 1 and 2 clinical trials of liraglutide with a focus on clinical pharmacology. Key findings: In early clinical trials of liraglutide, 0.05–1.9 mg daily improved multiple aspects of glycaemic control and beta-cell func
Autor:
Sibylle Koletzko, Antje Timmer, Jan Bornschein, Wolfgang Fischbach, Peter Layer, Joachim Labenz, Christian Prinz, Michael Vieth, S Suerbaum, W. E. Schmidt, Peter Malfertheiner, Jörg C. Hoffmann, J. C. Preiss, Gerhard Treiber, W Höhne, St Miehlke, Ulrich Peitz, W Bolten, Ulrich Rosien, O Götze, A Morgner, Manfred Kist, A Schwarzer
Publikováno v:
Zeitschrift für Gastroenterologie. 47:68-102
This guideline updates a prior concensus recommendation of the German Society for Digestive and Metabolic Diseases (DGVS) from 1996. It was developed by an interdisciplinary cooperation with representatives of the German Society for Microbiology, the
Publikováno v:
DMW - Deutsche Medizinische Wochenschrift. 125:455-458
HISTORY AND ADMISSION FINDINGS A 55-year-old woman had for 5 years been suffering from severe burning thoracic pain. She had typical risk factors for cardiovascular disease, namely hypertension, chronic smoking, obesity and hypercholesterolaemia. She
Publikováno v:
Journal of Physical Oceanography. 37:2920-2939
Surf-zone dispersion is studied using drifter observations collected within about 200 m of the shoreline (at depths of less than about 5 m) on a beach with approximately alongshore uniform bathymetry and waves. There were about 70 individual drifter
Publikováno v:
Der Internist. 48:698-707
Die Entwicklung einer Vielzahl neuer Substanzen wird das therapeutische Spektrum beim Typ-2-Diabetes in Zukunft deutlich erweitern. Bereits 2006 wurde der Endocannabinoidrezeptorantagonist Rimonabant fur die Therapie ubergewichtiger Patienten mit Typ
Autor:
R. H. Wittenberg, Matthias Heukamp, H. Knorth, B.M. Peskar, Peter Dorfmüller, Rainer Lebert, Roland E. Willburger, M. Wiese, W. E. Schmidt
Publikováno v:
Der Orthop�de. 34:241-249
Hintergrund Die In-vitro-Effekte selektiver COX-2-Inhibitoren (L-745,337, NS-398 und DFU) und des COX-unspezifischen Diclofenacs auf die Freisetzung von PGE2 und 6-keto-PGF1α aus Bursitis-subacromialis-Gewebe (BSG) von 35 Patienten mit Subakromialsy